Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis

Caldwell, 1999, Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease, Hepatology, 29, 664, 10.1002/hep.510290347

Matteoni, 1999, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology, 116, 1413, 10.1016/S0016-5085(99)70506-8

Oneta, 2002, Treatment options in non-alcoholic steatohepatitis according to pathogenic considerations, Swiss Med Wkly, 132, 493

Paumgartner, 2004, Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease, Clin Liver Dis, 8, 67, 10.1016/S1089-3261(03)00135-1

Laurin, 1996, Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study, Hepatology, 23, 1464, 10.1002/hep.510230624

Lindor, 2004, Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial, Hepatology, 39, 770, 10.1002/hep.20092

Strauss, 1999, Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a cross-sectional sample of obese and nonobese children (NHANES III), J Pediatr, 134, 160, 10.1016/S0022-3476(99)70409-9

Hasegawa, 2001, Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study, Aliment Pharmacol Ther, 15, 1667, 10.1046/j.1365-2036.2001.01083.x

Harrison, 2003, Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 98, 2485, 10.1111/j.1572-0241.2003.08699.x

Promrat, 2004, A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis, Hepatology, 39, 188, 10.1002/hep.20012

Ueno, 1997, Therapeutic effects of restricted diet and exercise in obese patients with fatty liver, J Hepatol, 27, 103, 10.1016/S0168-8278(97)80287-5

Suzuki, 2005, Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease, J Hepatol, 43, 1060, 10.1016/j.jhep.2005.06.008

Bugianesi, 2005, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease, Am J Gastroenterol, 100, 1082, 10.1111/j.1572-0241.2005.41583.x

Sanyal, 2004, A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 2, 1107, 10.1016/S1542-3565(04)00457-4

Kugelmas, 2003, Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E, Hepatology, 38, 413, 10.1053/jhep.2003.50316

Seki, 2002, In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases, J Hepatol, 37, 56, 10.1016/S0168-8278(02)00073-9

Chalasani, 2004, Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 99, 1497, 10.1111/j.1572-0241.2004.30159.x

Browning, 2004, Molecular mediators of hepatic steatosis and liver injury, J Clin Invest, 114, 147, 10.1172/JCI200422422

James, 1999, Non-alcoholic steatohepatitis: another disease of affluence, Lancet, 353, 1634, 10.1016/S0140-6736(99)00163-4

George, 1998, Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis, Gastroenterology, 114, 311, 10.1016/S0016-5085(98)70482-2

Bonkovsky, 1999, Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis, J Hepatol, 31, 421, 10.1016/S0168-8278(99)80032-4

Feldstein, 2003, Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis, Gastroenterology, 125, 437, 10.1016/S0016-5085(03)00907-7

Fromenty, 2004, The ins and outs of mitochondrial dysfunction in NASH, Diabetes Metab, 30, 121, 10.1016/S1262-3636(07)70098-8

Rodrigues, 2001, The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent, Expert Opin Investig Drugs, 10, 1243, 10.1517/13543784.10.7.1243

Rodrigues, 1998, Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production, Mol Med, 4, 165, 10.1007/BF03401914

Rodrigues, 1998, A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation, J Clin Invest, 101, 2790, 10.1172/JCI1325

Ratziu, 2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084

Brunt, 1999, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol, 94, 2467, 10.1111/j.1572-0241.1999.01377.x

Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701